The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of ...

Coccidioidomycosis has been associated with infliximab and etanercept therapy, but not with adalimumab therapy. The case presented here is not likely to be the only case of adalimumab-induced ...

Against an increased risk USA/Canada 1152 biologic users versus 7306 MTX users Retrospective cohort study Infliximab, etanercept and adalimumab. Pooled hazard ratio for hematologic malignancy ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Biologics approved by the Food and Drug Administration (FDA) for managing ulcerative colitis include: Anti-TNF agents, such ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people ...